Last reviewed · How we verify
PER-001 Intravitreal Implant - High Dose
PER-001 Intravitreal Implant - High Dose is a Small molecule drug developed by Perfuse Therapeutics, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | PER-001 Intravitreal Implant - High Dose |
|---|---|
| Sponsor | Perfuse Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of PER-001 in Participants With Open-Angle Glaucoma (PHASE1, PHASE2)
- A Study of PER-001 in Participants With Diabetic Retinopathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PER-001 Intravitreal Implant - High Dose CI brief — competitive landscape report
- PER-001 Intravitreal Implant - High Dose updates RSS · CI watch RSS
- Perfuse Therapeutics, Inc. portfolio CI
Frequently asked questions about PER-001 Intravitreal Implant - High Dose
What is PER-001 Intravitreal Implant - High Dose?
PER-001 Intravitreal Implant - High Dose is a Small molecule drug developed by Perfuse Therapeutics, Inc..
Who makes PER-001 Intravitreal Implant - High Dose?
PER-001 Intravitreal Implant - High Dose is developed by Perfuse Therapeutics, Inc. (see full Perfuse Therapeutics, Inc. pipeline at /company/perfuse-therapeutics-inc).
What development phase is PER-001 Intravitreal Implant - High Dose in?
PER-001 Intravitreal Implant - High Dose is in Phase 2.